Pulse Biosciences Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Pulse Biosciences Inc 's ROA in the second quarter of 2026?
Pulse Biosciences Inc recorded a cumulative net loss of $-80 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -79.96%.

However, within the Healthcare sector 694 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4145, from total ROA ranking in the first quarter of 2026 at 4738.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-3.9 %	-38.81 %	-25.34 %	22.47 %	235 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-80	-75	-73	-75	-68
Return On Assets (TTM)	-79.96 %	-73.61 %	-63.71 %	-61.13 %	-58.01 %
PLSE's Total Ranking	# 4145	# 4738	# 4130	# 4149	# 4270
Total Assets (TTM) in million	116	82	95	109	120
Seq. Total Assets Change	41.58 %	-13.66 %	-13.08 %	-9.55 %	-9.85 %
Seq. Net Income Change	-	-	-	-	-

PLSE's 5 Years Annual ROA >> Back to PLSE Management Effectiveness >> Compare PLSE ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 165
Sector	# 695
Overall	# 4143

Return On Assets Statistics
High	Average	Low
-38.45 %	-78.31 %	-118.13 %
(Dec 31 2016)		(Jun 30 2022)

News about Pulse Biosciences Inc Return on Assets ROA

Pulse Biosciences Unveils Promising Data from nPulse Cardiac Surgical System amidst Financial Struggles

Pulse Biosciences, Inc. (Nasdaq: PLSE), based in Hayward, California, has recently revealed late-breaking clinical data from its first-in-human feasibility study of the nPulse Cardiac Surgical System at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting held in Copenhagen, Denmark. This promising advancement underscores the company’s commitment to leveraging its innovative Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) technology, which aims to revolutionise cardiac surgery.The nPulse technology utilises a unique delivery method of energy that has shown considerable potential for precision in ablation processes. The ongoing feasibility study is pivotal as it seeks to evaluate the initial safety and effectiveness of the nPulse system, ultimately aiming to optimise patient outcomes in cardiac surgical procedures. Presenting at such a prestigious gathering of global cardiac and thoracic surgeons indicates a significant step forward for Pulse Biosciences in validating its technology in clinical settings.

Pulse Biosciences Takes a Major Leap Robert W. Duggan Exercises $58.4 Million in Warrants, Solidifying Company Growth...

Pulse Biosciences Takes a Major Leap: Robert W. Duggan Exercises $58.4 Million in Warrants, Solidifying Company Growth Pulse Biosciences, Inc. (Nasdaq: PLSE) continues to assert its position in the burgeoning field of bioelectric medicine with the recent announcement of a significant financial maneuver by its Co-Chairman and majority shareholder, Robert W. Duggan. On December 18, 2024, Duggan executed the full exercise of warrants acquired during the Company’s 2024 rights offering, a bold move that translates to an impressive $58.4 million and results in the issuance of 5,306,156 shares. The exercise of these warrants is a testament to Duggan’s confidence in the future potential of Pulse Biosciences and its innovative technology, the CellFX System. This system is underpinned by the pioneering Nano-Pulse Stimulation (NPS) technology, which has the capability to revolutionize the treatment landscape for various dermatological conditions. NPS is designed to deliver microsecond-duration electrical pulses, enabling targeted treatments that are both effective and minimally invasive compared to traditional methodologies.The timing of this financial decision is particularly strategic. As the healthcare industry increasingly shifts towards non-invasive treatment options that leverage cutting-edge technology, Pulse Biosciences stands out as a frontrunner. The significant infusion of capital from the warrant exercise will not only bolster the company’s operational capabilities but will also fuel its ongoing efforts in research and development, ensuring that it remains at the forefront of medical innovation.

Financial Statements
Pulse Biosciences Inc 's Assets	$ 116 million	PLSE's Balance sheet
Pulse Biosciences Inc 's Income	$ -25 million	Quarterly PLSE's Income Statement
PLSE's Income by Division		See PLSE's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-25.34 %	132.19 %	-21.48 %	44.39 %	39.46 %
Total Assets in million	95	127	55	69	48
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-73	-54	-42	-59	-64
Annual Return On Assets	-76.99 %	-42.32 %	-77.4 %	-84.24 %	-132.35 %

PLSE's 5 Years Annual ROA >> Back to PLSE Management Effectiveness >> Compare PLSE ROA to its Competitors

More Return On Assets Ratios
PLSE's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PLSE's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PLSE's Competitors
Subscribers only: Roa for Pulse Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for PLSE's Customers

You may also want to know
PLSE's Roi	PLSE's Inventory Turnover Ratio	PLSE's Growth Rates	PLSE's Dividend Comparisons
	PLSE's Profitability Ratios	PLSE's Asset Turnover Ratio	PLSE's Dividend Growth
PLSE's Roe	PLSE's Valuation Ratios	PLSE's Financial Strength Ratios	PLSE's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T21:36:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.